[Polyvinylpyridine N-oxide (Bay 3504, P-204, PVNO) in the treatment of human silicosis].
After having demonstrated the therapeutic effectiveness of polyvinylpyridine-N-oxide (PVNO) for experimental silicosis in numerous animal studies, and after having finalized the toxicological examinations, a tolerance test was run in a controlled clinical assay with human subjects. After having shown that PVNO infusions did not result in toxic side-effects its therapeutic effectiveness was clinically studied in two different cohorts: matched pairs studies were conducted in 8 miners (group 1) and in 20 stone-cutters (group 2). The study demonstrates the therapeutic potency of PVNO for man as well, subject to certain moderating conditions as follows: the degree of silicosis, the age of the silicotic focus and the dust-type influenced the outcome of the treatment. The minimal dose should be between 300 and 400 mg per kg bodyweight and should be given in intervals of one to two years.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008875:Middle Aged; D008906:Mining; D011144:Polyvinylpyridine N-Oxide / Q000627:therapeutic use*; D011145:Polyvinyls / Q000627:therapeutic use*; D012829:Silicosis / Q000188:drug therapy*
D011145:Polyvinyls; D011144:Polyvinylpyridine N-Oxide
Polyvinylpyridin-N-Oxid (Bay 3504, P-204, PVNO) in der Behandlung der Silikose des Menschen.